• Successful Phase II clinical trial of RECCE® 327 topical gel in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) including Diabetic Foot Infections (DFI)
• Approved Registrational Phase 3 DFI trial in Indonesia, expected to launch in 2026
• Promising preclinical data on using nebulized R327 to treat Mycobacterium abscessus lung infections

Recce Pharmaceuticals presented an overview of its key clinical and preclinical data at a Key Opinion Leader event. The company highlighted the successful results from its Phase II clinical trial of RECCE® 327 topical gel in Acute Bacterial Skin and Skin Structure Infections (ABSSSI), including Diabetic Foot Infections (DFI). The trial achieved all primary and secondary endpoints, with 93% of patients showing a successful clinical response at 14 days of treatment. The company also discussed its approved Registrational Phase 3 DFI trial in Indonesia, which is expected to launch in 2026 and will utilize the same endpoints as the successful Phase II study. Additionally, Recce presented promising preclinical data on the use of nebulized R327 to treat Mycobacterium abscessus lung infections, a significant challenge for patients with cystic fibrosis and other chronic lung diseases. The data demonstrated that R327 outperformed the current standard of care, clarithromycin, in treating M. abscessus infections in macrophages and mouse models, while also being safely tolerated when delivered to the lungs.Overall, the event highlighted Recce's progress in advancing its synthetic anti-infective technology, with late-stage clinical trials and a robust pipeline targeting critical unmet needs in infectious diseases.

Recce Pharmaceuticals is focused on advancing its pipeline, with the Registrational Phase 3 DFI trial in Indonesia expected to launch in 2026. The company is also exploring the use of nebulized R327 to treat Mycobacterium abscessus lung infections, a significant challenge for patients with cystic fibrosis and other chronic lung diseases.